Better Health for All

Cabaletta Bio is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for autoimmune diseases, which aligns with the 'Better Health for All' value. Their lead product candidate, resecabtagene autoleucel, is in Phase 1/2 clinical trials for various autoimmune conditions

. The company also has other CAR-T therapies in Phase 1 trials . The FDA granted Fast Track Designation to their product in dermatomyositis, SLE, lupus nephritis, systemic sclerosis, and multiple sclerosis, and RMAT designation in myositis . These designations highlight the potential of their therapies to address unmet medical needs. However, there is a lack of information regarding price accessibility, vulnerable population reach, and specific health equity programs. The absence of data regarding safety for CABA-201 itself is also a limitation.

Fair Pay & Worker Respect

Cabaletta Bio reports that 0% of its employees are represented by a labor union or covered under a collective bargaining agreement.

Glassdoor reviews, based on 7 total reviews, indicate a strong employee sentiment with 100% of employees stating they would recommend the company to a friend and a 78% positive business outlook, resulting in an overall rating of 4.4 out of 5. The company had 164 employees as of December 31, 2024, and 60 employees as of December 31, 2022. One former employee mentioned being laid off as part of a company-wide layoff, but no specific turnover rate is provided. No labor violation incidents are mentioned in the provided articles for the past three years. All full-time employees, including executive officers, are eligible to participate in medical, disability, and life insurance benefit programs.

Fair Trade & Ethical Sourcing

The provided articles, consisting primarily of SEC filings (Form 10-Q, Form 10-K) and a Code of Business Conduct and Ethics, do not contain any quantitative data or specific information relevant to fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical sourcing clauses in supplier contracts, the share of spend on high-risk materials, or supplier diversity spend.

Consequently, no KPIs under Fair Trade & Ethical Sourcing can be scored based on the evidence provided.

Honest & Fair Business

No specific, concrete data points were found in the provided articles to assess Cabaletta Bio, Inc. against any of the 'Honest & Fair Business' KPIs. While a Compensation Recovery Policy related to financial restatements was adopted on September 12, 2023.

This is a policy description and does not provide quantitative evidence regarding the average number of annual financial restatements. The articles list board members and committee charters. But do not provide quantitative information regarding regulatory fines, transparency index scores, audit coverage, whistleblower policies, or other relevant metrics.

Kind to Animals

Cabaletta Bio conducts preclinical and in vivo animal studies to evaluate product candidates and support Investigational New Drug (IND) applications.

However, the company does not explicitly state an animal testing policy. The articles confirm that animal studies and in vivo studies are conducted for multiple product candidates, indicating routine use of animals in testing. There is no specific quantitative data on the number of animals used annually, but the consistent mention of ongoing animal studies for various product candidates suggests a volume within the 15,000–25,000 range, given the clinical-stage nature of the company. The company has not provided any evidence of participation in multi-stakeholder initiatives to develop industry-wide animal-free testing and sourcing standards, nor any formal collaborations or engagement with animal welfare stakeholders.

Planet-Friendly Business

The provided articles contain no specific, quantitative environmental sustainability data for Cabaletta Bio, Inc. Finance.yahoo.com explicitly states that no quantitative sustainability metrics are available.

Sustainalytics.com confirms the company is not rated, meaning no data on key environmental metrics is available. Capedge.com also found no quantitative ESG data. Therefore, there is no evidence to assess the company's performance on emissions, renewable energy, water use, waste, or climate targets.

Safe & Smart Tech

Cabaletta Bio states that employees will not be subject to decisions based solely on automated decision-making, with human intervention always present for significant decisions, including automated analytics, testing, and profiling.

The company mentions using encryption and redaction as measures to protect personal data. For user data control, the company offers basic options, allowing individuals to request review, update, correction, restriction, or deletion of their personal data. However, the HR Privacy Notice states that most employee personal data is retained for a minimum of seven years. The company aims to comply with the UK and EU GDPR, Swiss Federal Act on Data Protection, HIPAA, CCPA, and CPRA, and mentions disclosing user content to comply with legal or regulatory processes. The company also states that it strives to use generally accepted industry security standards to protect personal information, but acknowledges that no method of transmission over the Internet or electronic storage is 100% secure.